306 related articles for article (PubMed ID: 24006085)
1. Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.
O'Hear C; Inaba H; Pounds S; Shi L; Dahl G; Bowman WP; Taub JW; Pui CH; Ribeiro RC; Coustan-Smith E; Campana D; Rubnitz JE
Cancer; 2013 Nov; 119(22):4036-43. PubMed ID: 24006085
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
Rubnitz JE; Inaba H; Dahl G; Ribeiro RC; Bowman WP; Taub J; Pounds S; Razzouk BI; Lacayo NJ; Cao X; Meshinchi S; Degar B; Airewele G; Raimondi SC; Onciu M; Coustan-Smith E; Downing JR; Leung W; Pui CH; Campana D
Lancet Oncol; 2010 Jun; 11(6):543-52. PubMed ID: 20451454
[TBL] [Abstract][Full Text] [Related]
3. MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.
Lambert J; Lambert J; Nibourel O; Pautas C; Hayette S; Cayuela JM; Terré C; Rousselot P; Dombret H; Chevret S; Preudhomme C; Castaigne S; Renneville A
Oncotarget; 2014 Aug; 5(15):6280-8. PubMed ID: 25026287
[TBL] [Abstract][Full Text] [Related]
4. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
[TBL] [Abstract][Full Text] [Related]
5. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.
Cooper TM; Franklin J; Gerbing RB; Alonzo TA; Hurwitz C; Raimondi SC; Hirsch B; Smith FO; Mathew P; Arceci RJ; Feusner J; Iannone R; Lavey RS; Meshinchi S; Gamis A
Cancer; 2012 Feb; 118(3):761-9. PubMed ID: 21766293
[TBL] [Abstract][Full Text] [Related]
6. Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.
Pilorge S; Rigaudeau S; Rabian F; Sarkozy C; Taksin AL; Farhat H; Merabet F; Ghez S; Raggueneau V; Terré C; Garcia I; Renneville A; Preudhomme C; Castaigne S; Rousselot P
Am J Hematol; 2014 Apr; 89(4):399-403. PubMed ID: 24375467
[TBL] [Abstract][Full Text] [Related]
7. Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia.
Wang ES; Zeidan A; Tan W; Wilding GE; Ford LA; Wallace PK; Hahn TE; Battiwalla M; McCarthy PL; Wetzler M
Leuk Lymphoma; 2012 Oct; 53(10):2085-8. PubMed ID: 21740302
[No Abstract] [Full Text] [Related]
8. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
Tavor S; Rahamim E; Sarid N; Rozovski U; Gibstein L; Aviv F; Kirsner I; Naparstek E
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):438-43. PubMed ID: 23017331
[TBL] [Abstract][Full Text] [Related]
9. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Jabbour E; Garcia-Manero G; Cortes J; Ravandi F; Plunkett W; Gandhi V; Faderl S; O'Brien S; Borthakur G; Kadia T; Burger J; Konopleva M; Brandt M; Huang X; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):244-51. PubMed ID: 22534616
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study.
Ito Y; Wakita A; Takada S; Mihara M; Gotoh M; Ohyashiki K; Ohtake S; Miyawaki S; Ohnishi K; Naoe T
Int J Hematol; 2012 Oct; 96(4):485-91. PubMed ID: 22956429
[TBL] [Abstract][Full Text] [Related]
11. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients.
Brunnberg U; Mohr M; Noppeney R; Dürk HA; Sauerland MC; Müller-Tidow C; Krug U; Koschmieder S; Kessler T; Mesters RM; Schulz C; Kosch M; Büchner T; Ehninger G; Dührsen U; Serve H; Berdel WE
Ann Oncol; 2012 Apr; 23(4):990-6. PubMed ID: 21810729
[TBL] [Abstract][Full Text] [Related]
12. Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients.
Serio B; Grimaldi F; Ammirati L; Annunziata M; De Santis G; Perrotta A; De Novellis D; Giudice V; Morini D; Storti G; Califano C; Risitano AM; Pane F; Selleri C
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2044. PubMed ID: 38662362
[TBL] [Abstract][Full Text] [Related]
13. Molecular response in two children with relapsed acute myeloid leukemia treated with a combination of gemtuzumab ozogamicin and cytarabine.
Brethon B; Auvrignon A; Cayuela JM; Lapillonne H; Leverger G; Baruchel A
Haematologica; 2006 Mar; 91(3):419-21. PubMed ID: 16531270
[TBL] [Abstract][Full Text] [Related]
14. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.
Burnett AK; Russell NH; Hills RK; Kell J; Freeman S; Kjeldsen L; Hunter AE; Yin J; Craddock CF; Dufva IH; Wheatley K; Milligan D
J Clin Oncol; 2012 Nov; 30(32):3924-31. PubMed ID: 22851554
[TBL] [Abstract][Full Text] [Related]
15. Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).
Amadori S; Suciu S; Stasi R; Salih HR; Selleslag D; Muus P; De Fabritiis P; Venditti A; Ho AD; Lübbert M; Thomas X; Latagliata R; Halkes CJ; Falzetti F; Magro D; Guimaraes JE; Berneman Z; Specchia G; Karrasch M; Fazi P; Vignetti M; Willemze R; de Witte T; Marie JP
J Clin Oncol; 2013 Dec; 31(35):4424-30. PubMed ID: 24127442
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML.
Jaramillo S; Krisam J; Le Cornet L; Kratzmann M; Baumann L; Sauer T; Crysandt M; Rank A; Behringer D; Teichmann L; Görner M; Trappe RU; Röllig C; Krause S; Hanoun M; Hopfer O; Held G; Buske S; Fransecky L; Kayser S; Schliemann C; Schaefer-Eckart K; Al-Fareh Y; Schubert J; Geer T; Kaufmann M; Brecht A; Niemann D; Kieser M; Bornhäuser M; Platzbecker U; Serve H; Baldus CD; Müller-Tidow C; Schlenk RF
Trials; 2021 Nov; 22(1):765. PubMed ID: 34732236
[TBL] [Abstract][Full Text] [Related]
17. Association of fludarabin, cytarabine, and fractioned gemtuzumab followed by hematopoietic stem cell transplantation for first-line refractory acute myeloid leukemia in children: A single-center experience.
Penel-Page M; Plesa A; Girard S; Marceau-Renaut A; Renard C; Bertrand Y
Pediatr Blood Cancer; 2020 Jun; 67(6):e28305. PubMed ID: 32307866
[TBL] [Abstract][Full Text] [Related]
18. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.
Gamis AS; Alonzo TA; Meshinchi S; Sung L; Gerbing RB; Raimondi SC; Hirsch BA; Kahwash SB; Heerema-McKenney A; Winter L; Glick K; Davies SM; Byron P; Smith FO; Aplenc R
J Clin Oncol; 2014 Sep; 32(27):3021-32. PubMed ID: 25092781
[TBL] [Abstract][Full Text] [Related]
19. Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials.
Li X; Xu SN; Qin DB; Tan Y; Gong Q; Chen JP
Ann Oncol; 2014 Feb; 25(2):455-61. PubMed ID: 24478322
[TBL] [Abstract][Full Text] [Related]
20. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
